Related Experiment Video
Updated: Jan 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies
Sukriti Krishan1,2, Jessica Koach1,2, Taylor Lim1,2
1Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales Sydney (UNSW), Sydney, NSW 2052, Australia.
Abstract:
MYCN and c-MYC are critical driver oncogenes in several childhood cancers, including neuroblastoma. Currently, the clinical development of MYC inhibitors has been hindered by the intrinsically disordered structure of MYC proteins, which lack well-defined ligand-binding pockets. Proliferation-associated protein 2G4 (PA2G4) directly binds to and stabilizes MYCN protein, leading to markedly increased MYCN levels in neuroblastoma cells. Here, we demonstrate that PA2G4 is essential for MYCN-driven tumor growth in neuroblastoma in vivo. Moreover, PA2G4 elevates c-MYC protein levels in neuroblastoma cells by inhibiting its ubiquitin-mediated degradation. In turn, c-MYC upregulates the transcription and protein expression of PA2G4, creating an oncogenic feed-forward expression loop. A small molecule PA2G4 inhibitor, WS6, directly disrupts the PA2G4-c-MYC protein-protein interaction, resulting in decreased levels of both PA2G4 and c-MYC. WS6 exhibited selective cytotoxicity in c-MYC-overexpressing cell lines. Together, these findings identify PA2G4 as a shared cofactor for both the c-MYC and MYCN oncoproteins and highlight its interaction with MYC family oncoproteins as a promising therapeutic vulnerability in MYC-driven cancers.
Insights
Proliferation-associated protein 2G4 (PA2G4) stabilizes MYCN and c-MYC oncoproteins, driving neuroblastoma growth. A novel inhibitor, WS6, disrupts this interaction, offering a potential therapeutic strategy for MYC-driven cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- MYCN and c-MYC are crucial oncogenes in pediatric cancers like neuroblastoma.
- Developing MYC inhibitors is challenging due to the proteins' disordered structures and lack of binding pockets.
Purpose of the Study:
- To investigate the role of Proliferation-associated protein 2G4 (PA2G4) in MYC-driven neuroblastoma.
- To explore PA2G4 as a potential therapeutic target in MYC-driven cancers.
Main Methods:
- Demonstrated PA2G4's essential role in MYCN-driven tumor growth in vivo.
- Investigated PA2G4's effect on c-MYC protein levels and degradation pathways.
- Utilized a small molecule PA2G4 inhibitor (WS6) to disrupt PA2G4-c-MYC interactions.
Main Results:
- PA2G4 directly binds and stabilizes MYCN, increasing its levels in neuroblastoma.
- PA2G4 inhibits c-MYC degradation, creating a feed-forward loop with c-MYC upregulating PA2G4.
- WS6 decreased PA2G4 and c-MYC levels and showed selective cytotoxicity in c-MYC-overexpressing cells.
Conclusions:
- PA2G4 acts as a shared cofactor for MYCN and c-MYC oncoproteins.
- The PA2G4-MYC interaction represents a promising therapeutic vulnerability in MYC-driven cancers.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic...
PI3K/mTOR/AKT Signaling Pathway
Master Transcription Regulators
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

